What Is Diphenhydramine HCL?

Diphenhydramine Hydrochloride English name Diphenhydramine Hydrochloride, molecular formula is C17H22ClNO, alias Benazin, Ketamine; chemical name is N, N-dimethyl-2- (diphenylmethoxy) ethylamine hydrochloride. Can eliminate allergic symptoms.

Diphenhydramine hydrochloride

Diphenhydramine Hydrochloride English name Diphenhydramine Hydrochloride, molecular formula is C17H22ClNO, alias
Can eliminate allergic symptoms. its
Method name: Determination of Diphenhydramine Hydrochloride-Neutralization Titration
Application range: This method uses the titration method to determine the content of diphenhydramine hydrochloride.
This method is applicable to diphenhydramine hydrochloride.
Principle of the method: After the test product is dissolved with glacial acetic acid and acetic anhydride, mercury acetate test solution and crystal violet indicator solution are added, and the solution is titrated with perchloric acid titration solution (0.1mol / L) until the solution is blue-green. The amount of fluid used is calculated.
Reagent: 1. Water (new boiling to room temperature)
2. Perchloric acid titrant (0.1mol / L)
3. Crystal violet indicator liquid
Acetic anhydride
5. Glacial acetic acid
6. Mercury acetate test solution
7. Reference Potassium Phthalate
Sample preparation: 1. Perchloric acid titration solution (0.1mol / L)
Preparation: Take 750mL of anhydrous glacial acetic acid (calculated with water content, add 5.22mL acetic anhydride per 1g of water), add 8.5mL perchloric acid (70% -72%), shake well, and slowly add acetic anhydride dropwise at room temperature. 23mL, shake while adding, shake evenly after adding, let cool, add an appropriate amount of anhydrous glacial acetic acid to 1000mL, shake well, and leave for 24 hours. If the test sample is easily acetylated, the water content on this page must be determined by moisture measurement, and then the water content of this solution should be adjusted to 0.01% -0.2% with water and acetic anhydride.
Calibration: Take about 0.16g of standard potassium hydrogen phthalate dried to constant weight at 105 , accurately weigh, add 20mL of anhydrous glacial acetic acid to dissolve, add 1 drop of crystal violet indicator solution, and titrate slowly with Blue, and the results of the titration are corrected with a blank test. Each 1mL of perchloric acid titration solution (0.1mol / L) is equivalent to 20.42mg of potassium hydrogen phthalate. Calculate the concentration of this solution based on the consumption of this solution and the amount of potassium hydrogen phthalate taken.
Storage: Place in a brown glass bottle and keep tightly closed.
Crystal violet indicator liquid
Take 0.5g of crystal violet, add 100mL of glacial acetic acid to dissolve, and get.
Operation steps: Accurately weigh 0.2g of the test sample, add 20mL of glacial acetic acid and 4mL of acetic anhydride, add 4mL of mercury acetate test solution and 1 drop of crystal violet indicator solution, and titrate with perchloric acid titrant (0.1mol / L) The solution was blue-green, and the titration result was corrected by a blank test. The volume of perchloric acid titrant consumed (mL) was recorded. Each 1 mL of perchloric acid titrant (0.1 mol / L) was equivalent to 29.18 mg of benzyl hydrochloride Lamin (C17H21NO · HCl), that is.
Note 1: "Precision weighing" means that the weighed weight should be accurate to one thousandth of the weight. Precision requirements.
References: Pharmacopoeia of the People's Republic of China, compiled by the National Pharmacopoeia Committee, Chemical Industry Press, 2005 edition, Part Two, p.528.
Common central inhibitory effects, such as drowsiness, dizziness, headache, dry mouth, nausea, vomiting, and discomfort in the upper abdomen. Rare side effects include shortness of breath, chest tightness, cough, and dystonia. It has been reported that closed teeth and laryngospasm can occur after administration. The elderly are prone to stagnation or dizziness for a long time after medication.
Oral: 12.5 mg per adult, 2 to 3 times daily. Children 2 to 3 times a day, 2.5 to 5 mg for children under 1 year old; 5 to 7.5 mg for children 1 to 3 years old; 7.5 to 10 mg for children 4 to 6 years old; and 10 to 12.5 mg for children over 7 years old.
When used to prevent motion sickness, it should be taken 1 to 2 hours before travelling, and at least 30 minutes before taking.
Overdose may cause confusion, convulsions, tremors, dyspnea, and hypotension. Overdose in infants and children can cause agitation, hallucinations, convulsions, and even death. If you take a toxic amount, you can use gastric lavage and catharsis. Diazepam can be controlled while convulsing. Hypotension can be treated symptomatically with vasoconstrictors. Others include oxygen and intravenous fluids and supportive care.
Pregnancy class B, pregnant women and lactating women should be used with caution, newborns and premature infants are contraindicated. In renal failure, the interval between dosing should be extended. Myasthenia gravis,
Toxicity data from literature and journals
Numbering
Toxicity type
testing method
Test object
Dosage used
Toxic effect
1
Acute toxicity
oral
child
12500 ug / kg
1. Behavioral toxicityconvulsions or seizure thresholds affected 2. Cardiotoxicityarrhythmia 3. Reproductive toxicityincreased mortality after implantation
2
Acute toxicity
oral
Adult male
10714 ug / kg
1. Autonomic neurotoxicity-affects parasympathetic nerves 2. Behavioral toxicity-hallucinations and perceptual distortions 3. Vascular toxicity-blood pressure height without autonomic ganglia
3
Acute toxicity
oral
Adult woman
83 mg / kg
1. Behavioral toxicityconvulsions or seizure thresholds affected 2. Behavioral toxicitycoma 3. Cardiotoxicityarrhythmia
4
Acute toxicity
Skin surface
child
60 mg / kg / 6H-I
1. Eye toxicity-not reported 2. Behavioral toxicity-Appearing hallucinations and perceptual distortion 3. Behavioral toxicity-Ataxia
5
Acute toxicity
oral
Rat
500 mg / kg
Detailed effects are not reported other than lethal dose
6
Acute toxicity
Intraperitoneal injection
Rat
82 mg / kg
Detailed effects are not reported other than lethal dose
7
Acute toxicity
Subcutaneous injection
Rat
201 mg / kg
Detailed effects are not reported other than lethal dose
8
Acute toxicity
Intravenous injection
Rat
35 mg / kg
1. Behavioral toxicity-changes in sleep time (including changes in righting reflex)
2. Behavioral toxicity-convulsions or seizure thresholds affected 3. Lung, chest or respiratory toxicity-dyspnea
9
Acute toxicity
oral
Mouse
164 mg / kg
Detailed effects are not reported other than lethal dose
10
Acute toxicity
Intraperitoneal injection
Mouse
56 mg / kg
1. Behavioral Toxicity-Convulsions or Seizure Thresholds Affected 2. Behavioral Toxicity-Excitement
11
Acute toxicity
Subcutaneous injection
Mouse
99200 ug / kg
1. Behavioral toxicity-lethargy 2. Behavioral toxicity-convulsions or seizure thresholds affected 3. Skin and accessory toxicity-changes in hair
12
Acute toxicity
Intravenous injection
Mouse
20 mg / kg
1. Behavioral toxicityconvulsions or seizure thresholds are affected 2. Behavioral toxicitychanges in exercise behavior (specific analysis)
3. Behavioral toxicity-ataxia
13
Acute toxicity
Intravenous injection
dog
24 mg / kg
1. Behavioral toxicity-lethargy 2. Behavioral toxicity-affected by convulsions or seizure thresholds 3. Behavioral toxicity-excitement
14
Acute toxicity
Intravenous injection
rabbit
10 mg / kg
1. Behavioral toxicity-convulsions or seizure thresholds are affected 2. Behavioral toxicity-excitement 3. Lung, chest or respiratory toxicity-difficulty breathing
15
Acute toxicity
oral
Guinea Pig
280 mg / kg
Detailed effects are not reported other than lethal dose
16
Acute toxicity
Intraperitoneal injection
Guinea Pig
75 mg / kg
Detailed effects are not reported other than lethal dose
17
Acute toxicity
Subcutaneous injection
Guinea Pig
40 mg / kg
1. Behavioral toxicity-tremor 2. Behavioral toxicity-convulsions or seizure thresholds affected 3. Behavioral toxicity-muscle contraction or spasm
18
Acute toxicity
Intravenous injection
Hamster
18 mg / kg
1. Behavioral toxicity-tremor 2. Behavioral toxicity-convulsions or seizure thresholds affected 3. Behavioral toxicity-excitement
19
Acute toxicity
Intramuscular injection
pigeon
63 mg / kg
1. Gastrointestinal toxicity-nausea, vomiting
20
Acute toxicity
Intraperitoneal injection
mammal
80 mg / kg
Detailed effects are not reported other than lethal dose
twenty one
Chronic toxicity
oral
Rat
1750 mg / kg / 14D-C
1. Chronic disease-related toxicity-death
twenty two
Chronic toxicity
oral
Rat
5687 mg / kg / 13W-C
1. Hepatotoxicity-hepatolenticular degeneration
twenty three
Chronic toxicity
Subcutaneous injection
Rat
6796 ug / kg / 14D-I
1. Nutrition and metabolic system toxicity-weight loss or weight loss rate reduction 2. Chronic disease related toxicity-changes in ovarian weight 3. Chronic disease related toxicity-changes in uterine weight
twenty four
Chronic toxicity
oral
Mouse
3706 mg / kg / 14D-C
1. Chronic disease-related toxicity-death
25
Chronic toxicity
oral
Mouse
3418 mg / kg / 13W-C
1. Chronic disease-related toxicity-death
26
Chronic toxicity
oral
dog
1440 mg / kg / 5W-I
1. Behavioral Toxicity-Excitement 2. Behavioral Toxicity-Ataxia
27
Mutation toxicity
Rat liver
100 umol / L
28
Mutation toxicity
Hamster lung
200 mg / L
29
Mutation toxicity
Hamster Ovary
100 mg / L
30
Carcinogenicity
oral
Rat
27037 mg / kg / 2Y-C
1. Carcinogenicity-may be carcinogenic (according to RTECS standards)
2. Brain toxicity-tumor
31
Reproductive toxicity
oral
Rat
1 mg / kg, 6-15 days after conception
1. Reproductive toxicity-fetal toxicity (such as fetal dysplasia but not death)
2. Reproductive toxicity-abnormal development of the urinary system
32
Reproductive toxicity
oral
Rat
39 mg / kg, 6-15 days after conception
1. Reproductive toxicity-increased mortality after implantation
33
Reproductive toxicity
Parenteral
Rat
12 mg / kg, 10 days after conception
1. Reproductive toxicity-abnormal skull and facial development (including nose / tongue)
2. Reproductive toxicity-abnormal development of musculoskeletal system 3. Reproductive toxicity-abnormal development of urinary system
34
Reproductive toxicity
Parenteral
Rat
48 mg / kg, 13-16 days after conception
1. Reproductive toxicity-other changes
35
Reproductive toxicity
Parenteral
Rat
12 mg / kg, 5 days after conception
1. Reproductive toxicity-increased mortality after implantation
36
Reproductive toxicity
oral
Mouse
420 mg / kg, 1 to 21 days after conception
1. Reproductive toxicity-stillbirth of the newborn 2. Reproductive toxicity-affects the vitality index of the newborn (if alive on the 4th day of birth)
37
Reproductive toxicity
oral
Mouse
4200 mg / kg, 1 to 21 days after conception
1. Reproductive toxicity-other changes
38
Reproductive toxicity
oral
Mouse
320 mg / kg, 11-14 days after conception
1. Reproductive toxicity-fetal toxicity (such as fetal dysplasia but not death)
39
Reproductive toxicity
oral
Mouse
800 mg / kg, 8-12 days after conception
1. Reproductive toxicity-reduced weight gain in newborns
40
Reproductive toxicity
Subcutaneous injection
Mouse
50 mg / kg, 8 days after female conception
1. Reproductive toxicity-fetal toxicity (such as fetal dysplasia but not death)
41
Reproductive toxicity
Subcutaneous injection
Mouse
100 mg / kg, 8 days after conception
1. Reproductive toxicity-abnormal development of the urinary system
42
Reproductive toxicity
Not reported
Mouse
1600 mg / kg, 6-15 days after conception
1. Reproductive toxicity-fetal toxicity (such as fetal dysplasia but not death)
[1-33]

IN OTHER LANGUAGES

Was this article helpful? Thanks for the feedback Thanks for the feedback

How can we help? How can we help?